Literature DB >> 29532180

Serotonergic Psychedelics: Experimental Approaches for Assessing Mechanisms of Action.

Clinton E Canal1.   

Abstract

Recent, well-controlled - albeit small-scale - clinical trials show that serotonergic psychedelics, including psilocybin and lysergic acid diethylamide, possess great promise for treating psychiatric disorders, including treatment-resistant depression. Additionally, fresh results from a deluge of clinical neuroimaging studies are unveiling the dynamic effects of serotonergic psychedelics on functional activity within, and connectivity across, discrete neural systems. These observations have led to testable hypotheses regarding neural processing mechanisms that contribute to psychedelic effects and therapeutic benefits. Despite these advances and a plethora of preclinical and clinical observations supporting a central role for brain serotonin 5-HT2A receptors in producing serotonergic psychedelic effects, lingering and new questions about mechanisms abound. These chiefly pertain to molecular neuropharmacology. This chapter is devoted to illuminating and discussing such questions in the context of preclinical experimental approaches for studying mechanisms of action of serotonergic psychedelics, classic and new.

Entities:  

Keywords:  5-HT2A; 5-HT2C; Cingulate cortex; Head-twitch; Ketanserin; Psychedelic mechanisms; Receptor binding; Receptor conformations; Receptor dimers; Receptor function; Serotonin; Signal transduction; α-Adrenergic

Mesh:

Substances:

Year:  2018        PMID: 29532180      PMCID: PMC6136989          DOI: 10.1007/164_2018_107

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  227 in total

1.  Receptors as drug targets.

Authors:  Michael Williams; Rita Raddatz
Journal:  Curr Protoc Pharmacol       Date:  2006-04

2.  Evidence for the preferential involvement of 5-HT2A serotonin receptors in stress- and drug-induced dopamine release in the rat medial prefrontal cortex.

Authors:  Elizabeth A Pehek; Christine Nocjar; Bryan L Roth; Tara A Byrd; Omar S Mabrouk
Journal:  Neuropsychopharmacology       Date:  2006-02       Impact factor: 7.853

3.  Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists.

Authors:  Michael R Braden; Jason C Parrish; John C Naylor; David E Nichols
Journal:  Mol Pharmacol       Date:  2006-09-25       Impact factor: 4.436

4.  An Efficient Metadynamics-Based Protocol To Model the Binding Affinity and the Transition State Ensemble of G-Protein-Coupled Receptor Ligands.

Authors:  Noureldin Saleh; Passainte Ibrahim; Giorgio Saladino; Francesco Luigi Gervasio; Timothy Clark
Journal:  J Chem Inf Model       Date:  2017-05-08       Impact factor: 4.956

5.  A possible correlation between drug-induced hallucinations in man and a behavioural response in mice.

Authors:  S J Corne; R W Pickering
Journal:  Psychopharmacologia       Date:  1967

6.  Discriminative stimulus properties of (+/-)-fenfluramine: the role of 5-HT2 receptor subtypes.

Authors:  Andrew C McCreary; Malgorzata Filip; Kathryn A Cunningham
Journal:  Behav Neurosci       Date:  2003-04       Impact factor: 1.912

7.  A homology-based model of the human 5-HT2A receptor derived from an in silico activated G-protein coupled receptor.

Authors:  James J Chambers; David E Nichols
Journal:  J Comput Aided Mol Des       Date:  2002-07       Impact factor: 3.686

8.  Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents.

Authors:  R A Glennon; M Titeler; J D McKenney
Journal:  Life Sci       Date:  1984-12-17       Impact factor: 5.037

9.  Psychopharmacological studies of lysergic acid diethylamide (LSD-25) intoxication; effects of premedication with BOL-128 (2-bromo-d-lysergic acid diethylamide), mescaline, atropine, amobarbital, and chlorpromazine.

Authors:  L D CLARK; E L BLISS
Journal:  AMA Arch Neurol Psychiatry       Date:  1957-12

10.  Shannon entropy of brain functional complex networks under the influence of the psychedelic Ayahuasca.

Authors:  A Viol; Fernanda Palhano-Fontes; Heloisa Onias; Draulio B de Araujo; G M Viswanathan
Journal:  Sci Rep       Date:  2017-08-07       Impact factor: 4.379

View more
  6 in total

1.  The adrenergic receptor antagonist carvedilol interacts with serotonin 2A receptors both in vitro and in vivo.

Authors:  Kevin Sean Murnane; Osman F Guner; J Phillip Bowen; Kalyn M Rambacher; Nader H Moniri; Tyler J Murphy; Cedrick Maceo Daphney; Aboagyewaah Oppong-Damoah; Kenner C Rice
Journal:  Pharmacol Biochem Behav       Date:  2019-04-15       Impact factor: 3.533

2.  Activity of Mitragyna speciosa ("Kratom") Alkaloids at Serotonin Receptors.

Authors:  Francisco León; Samuel Obeng; Marco Mottinelli; Yiming Chen; Tamara I King; Erin C Berthold; Shyam H Kamble; Luis F Restrepo; Avi Patel; Lea R Gamez-Jimenez; Carolina Lopera-Londoño; Takato Hiranita; Abhisheak Sharma; Aidan J Hampson; Clinton E Canal; Lance R McMahon; Christopher R McCurdy
Journal:  J Med Chem       Date:  2021-09-01       Impact factor: 8.039

3.  Serotonin 2A Receptor (5-HT2AR) Activation by 25H-NBOMe Positional Isomers: In Vitro Functional Evaluation and Molecular Docking.

Authors:  Eline Pottie; Olga V Kupriyanova; Asher L Brandt; Robert B Laprairie; Vadim A Shevyrin; Christophe P Stove
Journal:  ACS Pharmacol Transl Sci       Date:  2021-02-25

Review 4.  Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.

Authors:  Henry Lowe; Ngeh Toyang; Blair Steele; Justin Grant; Amza Ali; Lorenzo Gordon; Wilfred Ngwa
Journal:  Molecules       Date:  2022-04-14       Impact factor: 4.927

Review 5.  Changing the Cortical Conductor's Tempo: Neuromodulation of the Claustrum.

Authors:  Kelly L L Wong; Aditya Nair; George J Augustine
Journal:  Front Neural Circuits       Date:  2021-05-13       Impact factor: 3.492

Review 6.  The Therapeutic Potential of Psilocybin.

Authors:  Henry Lowe; Ngeh Toyang; Blair Steele; Henkel Valentine; Justin Grant; Amza Ali; Wilfred Ngwa; Lorenzo Gordon
Journal:  Molecules       Date:  2021-05-15       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.